Skinner Karen E, Haiderali Amin, Huang Min, Schwartzberg Lee S
Vector Oncology, an affiliate of ConcertAI, 6555 Quince, Suite 400, Memphis, TN 38119, USA.
Merck & Co., Inc., 351 N. Sumneytown Pike, North Wales, PA 19454, USA.
Future Oncol. 2021 Mar;17(8):931-941. doi: 10.2217/fon-2020-1021. Epub 2020 Nov 19.
This study examined treatment patterns and effectiveness outcomes of patients with metastatic triple-negative breast cancer (mTNBC) from US community oncology centers. Eligible patients were females, aged ≥18 years, diagnosed with mTNBC between 1 January 2010 and 31 January 2016. Kaplan-Meier and Cox regression methods were used. Sample comprised 608 patients with average age of 57.5 years and 505/608 patients (83.1%) received systemic treatment. Overall survival (OS) from first-line treatment found that African-American patients had shorter OS than White (9.3 vs 13.7 months; hazard ratio: 1.35; p = 0.006). More than 15% of women with mTNBC were not treated, indicating a high unmet need. Overall prognosis remains poor, which highlights the opportunity for newer therapies to improve progression-free survival and OS.
本研究调查了美国社区肿瘤中心转移性三阴性乳腺癌（mTNBC）患者的治疗模式及疗效结果。符合条件的患者为年龄≥18岁的女性，于2010年1月1日至2016年1月31日期间被诊断为mTNBC。采用了Kaplan-Meier法和Cox回归方法。样本包括608例患者，平均年龄57.5岁，其中505/608例患者（83.1%）接受了全身治疗。一线治疗的总生存期（OS）发现，非裔美国患者的OS短于白人患者（9.3个月对13.7个月；风险比：1.35；p = 0.006）。超过15%的mTNBC女性未接受治疗，表明存在高度未满足的需求。总体预后仍然很差，这凸显了新型疗法改善无进展生存期和总生存期的机会。
